OrphoMed: OrphoMed Resumes Recruitment for Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D

(marketscreener.com) OrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics, today announced resumption of patient recruitment for its Phase 2 trial of ORP-101 for treatment of irritable bowel syndrome with diarrhea . OrphoMed paused screening of new patients on March 27, 2020, in response to the COVID-19 pandemic....https://www.marketscreener.com/news/OrphoMed-Resumes-Recruitment-for-Phase-2-Adaptive-Design-Study-of-ORP-101-for-Treatment-of-IBS-D--30709843/?utm_medium=RSS&utm_content=20200602